To improve current cancer immunotherapies, strategies to modulate various immunosuppressive cells including myeloid derived suppressor cells (MDSC) which were shown to be negative factors in immune-checkpoint blockade therapy, need to be developed. In the present study, we evaluated the role of the local reninangiotensin system (RAS) in the tumor immune-microenvironment using murine models bearing tumor cell lines in which RAS was not involved in their proliferation and angiogenetic ability. Giving angiotensin II receptor blockers (ARB) to Abbreviations: ACE, angiotensin-converting enzyme; Ang II, angiotensin II; ARB, angiotensin II receptor blocker; AT1R, type I angiotensin receptor; ATCC, American Type Culture Collection;
by reducing cancer-associated immunosuppression. 7, 8 Several studies have shown that currently used molecular target drugs for these pathways have synergistic anti-tumor effects when combined with immunotherapies through immune-related mechanisms. [9] [10] [11] Renin-angiotensin system is generally thought of as an endocrine system that regulates hydromineral balance and blood pressure systemically. However, recent data have demonstrated that renin and angiotensinogen genes and their products, known as local RAS, are also expressed locally at many tissue sites, where they serve as fundamental regulators of many additional physiological and pathophysiological processes. 12 In cancer microenvironments, the major components of RAS are expressed in cancer cells as well as in stromal cells, such as macrophages and CAF. 12 This local RAS in cancer tissues has been reported to be involved in cellular migration, proliferation, inflammation, and angiogenesis in the tumor and supporting stromal cells. 18 were bred in our animal facility.
All animal experiments in our study have been approved by the ethics committee on animal research of Keio University School of Medicine.
| Real-time RT-PCR
Total RNA and cDNA synthesis and real-time RT-PCR were carried out using standard protocols. Primers for the target genes are listed in Appendix S1.
| WST-1 cell proliferation analysis
Cancer cell proliferation was evaluated using WST- randomly chosen images at 209 magnification) of the sorted cells were positive for both GFP and HSP47, a fibroblast marker (Fig. S1 ).
For further details and antibodies, see Appendix S1.
| Immunohistochemistry
Immunohistochemistry was done on frozen sections (for CD8) or formalin-fixed paraffin-embedded sections (for CD31) of MC38 tumor tissues using standard protocols as previously described. 20 For further details and antibodies, see Appendix S1. 
| T-cell proliferation assay

| Statistical analysis
All results are expressed as mean AE SD. Data were subjected to statistical analysis (unpaired t test and Bonferroni/Dunn's test) to determine differences among the means of the experimental, treated, and control groups. Differences were considered to be statistically significant at P < .05. Next, we evaluated whether RAS might directly affect IL-6 production from CD11b + cells. mRNA of AT1R was expressed on the tumor-infiltrating CD11b + cells (Fig. S4d) . Increased IL-6 production accompanied by activation of NF-jB, a representative transcriptional factor regulating IL-6 mRNA expression, was observed in in vitro
Ang II-treated tumor-infiltrating CD11b + CD11c À cells isolated from naive C57BL/6 mice, an effect that was inhibited by valsartan (Figure 2F ,G). This demonstrates a direct effect of RAS on macrophages and MDSC.
Because inhibiting RAS has been reported to have suppressive effects on DC in vitro or in AT1R knockout mice 23 and to induce
Treg in autoimmunity models, 24 we analyzed in vivo phenotypic changes of them in valsartan-treated MC38-bearing mice and found that the treatment affected neither T-cell stimulatory activity of DC ( This particular effect is inhibited by appropriate doses of ARB without affecting DC and Treg.
| ARB treatment augmented the T-cell stimulatory activity of CAF
Fibroblasts from various organs have been reported to express AT1R.
CAF from the MC38 tumor tissue in this experiment also express AT1R (Fig. S4d) . Ang II stimulates their proliferation and induces Figure 3A,B) , both of which are related to the inhibition of anti-tumor immune responses. [28] [29] [30] [31] When evaluating the effect of CAF on T-cell proliferation in vitro, CAF from valsartan-treated mice showed T-cell stimulatory activities, whereas CAF from control mice had no effect on T-cell proliferation (Figure 3C) . These results suggest that local RAS in the tumor microenvironment might contribute to the immunosuppressive character of CAF, an effect that can be altered by ARB treatment.
| Combined therapy with ARB and anti-PD-L1
antibody showed synergistic anti-tumor effects 
F I G U R E 3 Angiotensin-renin blockade increased T-cell stimulatory function of cancer-associated fibroblasts and decreased their expression of nitric oxide synthase (NOS)2 and chemokine (C-X-C motif) ligand (CXCL12). A, Genes expressed in cancer-associated fibroblasts (CAF) were measured by quantitative PCR (qPCR). Levels are normalized to the control. B, NOS activity of CAF was measured using ultrasensitive colorimetric NOS assay kits. C, Murine CAF were isolated from dsRed-labeled MC38 tumor-bearing enhanced green fluorescent protein (EGFP) mice (n = 3). CAF were irradiated and cocultured with T cells from C57BL/6 mice in the presence of anti-CD3-Ab for 3 days. T-cell proliferation was measured by BrdU incorporation. T cells incubated without CAF (1:0) served as a negative control and BrdU incorporation level in this group was defined as 1. All data in Figure 3 are from 3 independent experiments. Error bars indicate SD. *P < .05 using a t test.
infiltration of tumor antigen-specific T cells, leading to enhanced anti-tumor efficacy of anti PD-L1 Ab therapies.
In animal models, accumulating evidence indicates that inhibition of RAS suppresses tumor growth mainly by inhibiting angiogenesis. 13, 34 In our mouse model using MC38, although VEGF production from CD11b + cells was reduced, angiogenesis evalu- ) were s.c. injected into C57BL/6 mice on day 0. Anti-PD-L1 antibody or isotype antibody (200 lg) was given on days 7, 10, and 13. Rat anti-mouse CD8 or isotype antibody (200 lg) was given i.p. 1 day before tumor implantation and on days 4, 5, 6, 12, and 19 after tumor implantation. Tumor volumes were measured every 3-4 days. Mean tumor size AE SD (n = 5). All data are from 3 independent experiments. *P < .05 comparing untreated mice (control) with valsartan + anti-PD-L1 antibodytreated mice. B, PD-L1 expression levels of MC38 cultured with various concentrations of angiotensin II and valsartan in vitro were measured by flow cytometry. All data are from 3 independent experiments. Error bars indicate SD. C, PD-L1 expression levels of MC38 tumor from the untreated or valsartan-administered mouse were measured by flow cytometry. All data are from 2 independent experiments. Error bars indicate SD. *P < .05 using a t test. n.s., not significant in myeloid-mediated immune responses against cancers has not been well addressed. Furthermore, although Ang peptide levels have been reported to be elevated in some patients with cancer, this is not always the case. 38, 39 In our study, plasma Ang II was not elevated in phages characterized by high IL-12. 40 As for MDSC, the number of CD11b + Gr-1 + cells were decreased in the spleens of ACE 10/ 10 mice. 41 Unlike our findings, these observations suggest that ACE in macrophages and MDSC has anti-tumor properties. However, the expression of ACE in that model was much higher than physiological levels, and these phenotypes of tumor-bearing ACE 10/10 mice were not critically dependent on the AT1R signal, because ARB could not reverse these phenotypes in that study. Ab in a pancreatic cancer model. 28 These studies have shown in vivo immunosuppressive roles for CAF. Although CAF expressing AT1R 27 and Ang II were reported to be involved in fibroblast proliferation and secretion of some of the above immunosuppressive factors, the role of RAS in CAF-mediated anti-tumor immune responses has not been well evaluated. Our study suggests that local RAS is involved in generating CAF immunosuppressive properties by enhancing its NOS2 and CXCL12 expression, effects that could be modified by ARB treatment.
Several retrospective evaluations of the effects of ACE inhibitors or ARB treatment on cancer incidence have produced conflicting conclusions. Decreases, 45 increases, 46 and no change 47 in cancer incidence have been reported. However, the concurrent use of ARB with chemotherapy has shown synergistic clinical effects in many studies.
Recently, it has been reported that the composition, localization, and function of tumor-infiltrating lymphoid and myeloid cells, called the immune contexture, has major prognostic value in cancer patients treated with chemotherapy. 48 One of the mechanisms of these synergistic effects might be improvement of the cancer immunological microenvironment by ACE inhibitors or ARB as shown in our study.
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